These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32566431)

  • 1. Correction: Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy.
    Eren T; Pasaoglu L
    Cureus; 2020 Jun; 12(6):c32. PubMed ID: 32566431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy.
    Eren T; Pasaoglu L
    Cureus; 2020 Mar; 12(3):e7230. PubMed ID: 32280572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of portal hypertension after the treatment of oxaliplatin based adjuvant chemotherapy for rectal cancer].
    Heo J; Shin KY; Kwon YH; Park SY; Jung MK; Cho CM; Tak WY; Kweon YO
    Korean J Gastroenterol; 2011 Apr; 57(4):253-7. PubMed ID: 21519180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment continuation with a single mild partial splenic embolization for thrombocytopenia caused by oxaliplatin-based chemotherapy for advanced colon cancer.
    Heianna J; Muto O; Miyauchi T; Endo W; Togashi A; Azama K; Murayama S
    Indian J Gastroenterol; 2016 May; 35(3):245-7. PubMed ID: 27230031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
    Angitapalli R; Litwin AM; Kumar PR; Nasser E; Lombardo J; Mashtare T; Wilding GE; Fakih MG
    Oncology; 2009; 76(5):363-8. PubMed ID: 19321964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
    Brungs D; Aghmesheh M; de Souza P; Carolan M; Clingan P; Rose J; Ranson M
    Clin Colorectal Cancer; 2018 Sep; 17(3):e549-e555. PubMed ID: 29861156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
    Shah MA; Renfro LA; Allegra CJ; André T; de Gramont A; Schmoll HJ; Haller DG; Alberts SR; Yothers G; Sargent DJ
    J Clin Oncol; 2016 Mar; 34(8):843-53. PubMed ID: 26811529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
    Kim MJ; Han SW; Lee DW; Cha Y; Lee KH; Kim TY; Oh DY; Kim SH; Im SA; Bang YJ; Kim TY
    Cancer Res Treat; 2016 Jul; 48(3):990-7. PubMed ID: 26790967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study.
    Liang YH; Shao YY; Chen HM; Cheng AL; Lai MS; Yeh KH
    Anticancer Res; 2017 Dec; 37(12):7095-7104. PubMed ID: 29187501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
    J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study.
    Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Higuera O; Burgos E; Ramos D; Calatrava A; Andrada E; López R; Moreno V; Madero R; Cejas P; Feliu J
    Ann Oncol; 2014 Feb; 25(2):398-403. PubMed ID: 24351404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.
    Vernieri C; Galli F; Ferrari L; Marchetti P; Lonardi S; Maiello E; Iaffaioli RV; Zampino MG; Zaniboni A; De Placido S; Banzi M; Damiani A; Ferrari D; Rosati G; Labianca RF; Bidoli P; Frassineti GL; Nicolini M; Pavesi L; Tronconi MC; Buonadonna A; Ferrario S; Re GL; Adamo V; Tamburini E; Clerico M; Giordani P; Leonardi F; Barni S; Ciarlo A; Cavanna L; Gori S; Cinieri S; Faedi M; Aglietta M; Antista M; Dotti KF; Galli F; Di Bartolomeo M;
    Oncologist; 2019 Mar; 24(3):385-393. PubMed ID: 30606884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
    Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A
    J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression.
    Pantarotto M; Barata R; Coelho R; Sousa V; Carvalheiro C; Rolim I; Garrido P; GIl N; Duarte-Ramos F; Tonin FS
    Cureus; 2023 Feb; 15(2):c101. PubMed ID: 36819952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
    Lieu C; Kennedy EB; Bergsland E; Berlin J; George TJ; Gill S; Gold PJ; Hantel A; Jones L; Mahmoud N; Meyerhardt J; Morris AM; Ruíz-García E; You YN; Baxter N
    J Clin Oncol; 2019 Jun; 37(16):1436-1447. PubMed ID: 30986117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.
    Park YS; Ji J; Zalcberg JR; El-Serafi M; Buzaid A; Ghosn M
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):334-42. PubMed ID: 26471890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.
    Tang M; Price TJ; Shapiro J; Gibbs P; Haller DG; Arnold D; Peeters M; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):339-349. PubMed ID: 29478352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].
    Zaanan A; Taieb J
    Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy in resected colon cancer: When, how and how long?
    Gelibter AJ; Caponnetto S; Urbano F; Emiliani A; Scagnoli S; Sirgiovanni G; Napoli VM; Cortesi E
    Surg Oncol; 2019 Sep; 30():100-107. PubMed ID: 31500770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.